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National Taiwan University Hospital, Taiwan Background and Aims: Lung cancer in never-smoker is a distinct disease and prevalent in East Asia. The study is aiming to perform low dose CT (LDCT) screening for lung cancer in never-smokers and validate the risk SNPs previously identified that associated with susceptibility to lung cancer in never-smokers (TALENT: Taiwan Lung Cancer Screening for Never-smoker Trial)
Methods: This is a prospective, nationwide, multicenter study sponsored by The Ministry of Health and Welfare, Taiwan. The inclusion criteria were age between 55-75 years, never-smokers with one of the following risk: family history of lung cancer within third-degree, passive smoking exposure, TB/COPD, cooking index ≥ 110, and not using ventilator during cooking. The LDCT was conducted according to the ACR guideline. A solid or part-solid nodule 6 mm or pure ground glass nodule 5 mm in diameter was designated as positive on LDCT. The PBMC DNA was obtained for SNP typing (TERT, TP63, HLA-DRB1/HLA-DQA1, HLA-DRB9/HLA-DRB5, VTI1A, BPTF and DCBLD1).
Results: This is the interim report. Till May 13, 2018, totally 10,397 subjects were enrolled, 329 underwent diagnostic procedures (31 by bronchoscopy or CT guided, 298 by surgery). The final diagnosis included 12 atypical adenomatous hyperplasia, 42 adenocarcinoma in situ, 46 minimally invasive adenocarcinoma, 152 invasive lung adenocarcinoma (stage IA 118, IB 23, IIA 2, IIB 1, IIIA 2, IV 5, and unknown 1), one adenosquamous cell carcinoma, one squamous cell carcinoma, one small cell carcinoma, 66 benign lesions and 8 others. The lung cancer detection rate was 2.34% (243/10,397) and 94.7% stage I. The genotyping showed 3 SNPs(TERT, TP63, HLA-DRB1/HLA-DQA1)were significantly associated with the risk of lung cancer in never-smokers.
Conclusion:
Our study revealed that the lung cancer detection rate by LDCT in high-risk never-smokers was even higher than that of the high-risk smoking group in NLST. We validated 3 SNPs that associated with susceptibility to lung cancer in never-smokers. 
NHO Higashihiroshima Medical Center, Japan
Background and Aims: To improve the specificity of screening programs for the early detection of lung cancer, novel strategies for identifying individuals at high risk or extremely low risk of lung cancer should be investigated. Based on the hypothesis that similar molecular alterations may occur in the lungs and oral cavity because the entire airway is exposed to the same inhaled carcinogens, we analyzed DNA methylation profiles in the oral epithelium for lung cancer risk stratification.
Methods: Methylation-specific polymerase chain reaction (MS-PCR)
was performed using the oral epithelium in 40 patients with lung cancer and 152 individuals without lung cancer (controls). As we have demonstrated that DNA methylation of GDNF, RARB, ProK, HOXD11, and PCDHGB6 in the oral epithelium might be promising biomarkers for lung cancer risk stratification in a pilot analysis using a small sample, MS-PCR was performed using the oral epithelium, and DNA methylation profiles were compared between patients and controls in the 192 enrolled participants.
Results:
The MS-PCR analysis revealed that GDNF, RARB, and HOXD11 were more frequently methylated in patients than in controls (P = 0.0026, P = 0.0170 and P = 0.0335, respectively). Combined analyses indicated that 12 of 40 (30%) patients and 10 of 152 (6.6%) controls showed DNA methylation in 2-3 genes (P < 0.0001). In a subgroup analysis limited to non-smokers, 5 of 12 (41.7%) patients showed methylation in 2-3 genes, compared to 4 of 95 (4.2%) controls (P < 0.0001). Among the population aged >50 years, 12 of 40 (30%) patients and 9 of 63 (14.3%) controls showed methylation in both genes (P = 0.0537).
Conclusion:
Results of this study demonstrate that risk stratification for lung cancer screening through DNA methylation analysis in the oral epithelium may be an ideal strategy, because it can be performed in a less-invasive manner.
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